First-line systemic treatment patterns and outcomes in lung cancer patients with malignant pleural effusion: a retrospective multicenter study.
Adding bevacizumab to chemotherapy improved survival in lung cancer patients with fluid around the lungs who lacked genetic driver mutations.
This PubMed-indexed study examined first-line systemic treatment patterns and outcomes in lung cancer patients with malignant pleural effusion: a retrospective multicenter study. First-line systemic therapy was associated with improved survival in lung cancer patients with MPE, though outcomes differed according to histologic and molecular subtypes The addition of bevacizumab to chemotherapy was independently associated with longer OS among patients with driver gene-negative NSCLC with MPE.
What the study was
- Study design
- Retrospective multicenter cohort study
- Population
- Human participants or human evidence described in the PubMed abstract
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Journal of thoracic disease
Why it surfaced
Retrospective multicenter cohort study with PubMed abstract evidence; scored conservatively for genomics/precision medicine relevance and evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.